RxDoctor Payments Data

Hemant Sheth

Pulmonary Disease · Saint Joseph, MONPI 1134140270

Payments from drug & device makers

$232in general payments, 2019–2025

Across 12 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$89
  • Boehringer Ingelheim$28
  • Pulmonx Corporation$22
  • Insmed, Inc.$22
  • GSK$20
  • Viatris Specialty LLC$18
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$22195%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$232 in reported general payments places this provider in the 20th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$218,915
Medicare patients
511
Services billed
2,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva HandihalerTiotropium Bromide94$99,991
Advair HfaFluticasone Propion/Salmeterol55$41,334
SymbicortBudesonide/Formoterol Fumarate84$40,801
Fluticasone-SalmeterolFluticasone Propion/Salmeterol91$25,897
Incruse ElliptaUmeclidinium Bromide41$19,383
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,640
DuleraMometasone/Formoterol13$10,995
Albuterol Sulfate HfaAlbuterol Sulfate226$9,900
Tiotropium Bromide13$9,608
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,571
ArexvyRsvpref3 Antigen/As01e/Pf19$5,344
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$5,260
Wixela InhubFluticasone Propion/Salmeterol15$4,956
Montelukast Sodium317$3,244
Ventolin HfaAlbuterol Sulfate31$3,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKIncruse Ellipta, Trelegy Ellipta, Anoro Ellipta, Arexvy$20$46,93896 claims
AstraZenecaSymbicort$89$40,80184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →